- Previous Close
5.47 - Open
5.50 - Bid 5.54 x 900
- Ask 5.60 x 200
- Day's Range
5.42 - 5.63 - 52 Week Range
2.41 - 12.22 - Volume
390,085 - Avg. Volume
904,637 - Market Cap (intraday)
453.568M - Beta (5Y Monthly) 2.36
- PE Ratio (TTM)
-- - EPS (TTM)
-2.04 - Earnings Date Oct 31, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
26.25
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
www.mindmed.coRecent News: MNMD
View More
Performance Overview: MNMD
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MNMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MNMD
View MoreValuation Measures
Market Cap
444.68M
Enterprise Value
225.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.20
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.57%
Return on Equity (ttm)
-66.26%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-102.04M
Diluted EPS (ttm)
-2.04
Balance Sheet and Cash Flow
Total Cash (mrq)
243.13M
Total Debt/Equity (mrq)
12.00%
Levered Free Cash Flow (ttm)
-32.17M
Research Analysis: MNMD
View MoreCompany Insights: MNMD
MNMD does not have Company Insights